Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 11 I, 2005, Pages 2579-2583

  Hess, Lisa M ^a   Saboda, Kathylynn ^a   Malone, Daniel C ^b   Salasche, Stuart ^a   Warneke, James ^a   Alberts, David S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFLORNITHINE; PLACEBO; TRIAMCINOLONE;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTAINER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SKIN CANCER; TOPICAL TREATMENT; WEIGHT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; EFLORNITHINE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PLACEBOS; SKIN NEOPLASMS; TRIAMCINOLONE; TRUTH DISCLOSURE;

EID: 28644434323     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0104     Document Type: Article

References (12)

1. Dunbar JM, Stunkard AJ. Adherence to diet and drug regimen. In: Levy R, Rifkind B, Dennis B, Ernst N, editors. Nutrition, lipids, and coronary heart disease. New York: Raven Press; 1979.
2. Switzer BR, Stark AH, Atwood JR, Ritenbaugh C, Travis RG, Wu HM. Development of a urinary riboflavin adherence marker for a wheat bran fiber community intervention trial. Cancer Epidemiol Biomarkers Prev 1997;6:439-42.
3. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074-90; discussion 1073.
4. Huang HY, Maguire MG, Miller ER III, Appel LJ. Impact of pill organizers and blister packs on adherence to pill taking in two vitamin supplementation trials. Am J Epidemiol 2000;152:780-7.
5. Dunbar J. Adherence measures and their utility. Control Clin Trials 1984;5:515-21.
6. Wang PS, Benner JS, Glynn RJ, Winkelmayer WC, Mogun H, Avorn J. How well do patients report noncompliance with antihypertensive medications? A comparison of self-report versus filled prescriptions. Pharmacoepidemiol Drug Saf 2004;13:11-9.
7. Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, Ltd.; 1991.
8. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials 2000;21:188-94S.
9. Shumaker SA, Rejeski WJ. Adherence to behavioral and pharmacological interventions in clinical research on older adults. Control Clin Trials 2000;21:S155.
10. Enstrom I, Pennert K, Lindholm LH. Durability of improvement achieved in a clinical trial. Is compliance an issue? J Fam Pract 2000;49:634-7.
11. Kastrissios H, Suarez JR, Hammer S, Katzenstein D, Blaschke TF. The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. AIDS 1998;12:2305-11.
12. Maenpaa H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987;8 Suppl I:39-43.